An experimental weekly injection called retatrutide helped adults with obesity lose an average of 25 percent of their starting weight after 80 weeks in a phase 3 clinical trial published in The New England Journal of Medicine.
Participants Achieve Twenty Five Percent Weight Loss
At the highest dose, average weight loss reached 25 percent of starting weight. Individuals in the 4-milligram group experienced a 17.6 percent reduction, while those taking 9 milligrams saw a 23.7 percent drop.
These figures reflect averages from participants who entered the extension phase rather than the entire original enrollment group.
The trial, led by Ania Jastreboff at Yale University, enrolled 2,339 adults with obesity who did not have diabetes.
How Retatrutide Targets Multiple Hormone Receptors
Retatrutide functions as a triple agonist, activating receptors for three distinct chemical messengers that regulate nutrients, blood sugar, and appetite after a meal. The drug targets GLP-1, GIP, and the glucagon receptor, which helps the liver release glucose and increase energy expenditure.
This multi-hormone approach combines appetite reduction with increased energy use. Unlike Wegovy, which targets the GLP-1 pathway, or Mounjaro, which combines GLP-1 and GIP, retatrutide also engages the glucagon receptor. FDA approval. Eli Lilly chief scientific and product officer Daniel Skovronsky stated that the trial achieved a new high-water mark for potential weight loss.
Impact on Knee Pain and Sleep Apnea
Beyond weight reduction, researchers tracked physical complications associated with obesity, including knee osteoarthritis and breathing disruptions during sleep.
Among 574 participants with knee osteoarthritis, pain decreased. In an analysis accounting for other events and treatment discontinuation, pain scores on a 0–10 scale fell by an average of 4.1 points with 12 milligrams, compared with 2.5 points for the placebo group. Another 243 participants had obstructive sleep apnea.
Separate Trial Evaluates Patients with Type Two Diabetes
While the Yale-led trial focused on adults without diabetes, a separate phase 3 clinical trial designated TRIUMPH-2 evaluated 1,152 people with obesity and type 2 diabetes.
In the diabetes study, patients taking the 12-milligram dose lost an average of 49.6 pounds, or 18.8 percent of their body weight, alongside improvements in blood sugar, cholesterol, and blood pressure. According to Eli Lilly, those in the 4-mg group lost an average of 29.8 pounds, and those taking 9 mg lost an average of 45.4 pounds. Randy Seeley, a professor at the University of Michigan, noted that patients with diabetes generally lose less weight on GLP-1 medications than those without diabetes.
Other Amylin Pathway Developments
Eli Lilly is also testing eloralintide, an experimental drug targeting the amylin pathway. In a phase 2 trial for patients with obesity and type 2 diabetes, a combination of eloralintide and tirzepatide led to an average weight loss of 54.1 pounds at 48 weeks at the highest dose. Eloralintide alone at 6 mg resulted in average weight loss of up to 28.6 pounds, while Zepbound 15 mg alone resulted in 34.4 pounds.
However, side effects led 10.8% to 27% of patients taking both drugs to stop treatment, compared to 2.9% for those on tirzepatide alone. Bikman stated, “A therapy is only effective if patients can remain on it, so tolerability in Phase 3 will be as important as efficacy.” Leerink Partners analyst David Risinger predicts eloralintide products could reach $23.2 billion in annual sales by the end of 2035. Other firms, including AstraZeneca, Pfizer, and Viking Therapeutics, are also developing amylin products.
Frequently Asked Questions
What exact hormone receptors does retatrutide activate?
Retatrutide activates receptors for three chemical messengers: GLP-1, GIP, and glucagon.
How many participants enrolled in the diabetes-specific trial?
The TRIUMPH-2 trial enrolled 1,152 people with obesity and type 2 diabetes across eight countries.
Retatrutide has not yet been approved by any regulatory agency.
Worth a look